This designation is meaningful as it signifies our continued commitment to making biosimilars more accessible. Both biosimilars and interchangeable biosimilars are highly similar and have no ...

The center, located at the Texas Medical Center, aims to revolutionize pediatric cancer care by integrating resources and ...

This drugmaker achieved a milestone - its first quarterly profit. But the stock is down despite the good tidings.

Addition of commercial-scale sterile injectables capabilities in Lexington, KYAddition of development and commercial-scale ...

Here's our list of the leaders in Massachusetts tech, biotech and climate tech who aren't just surviving, but moving their ...

In April 2025, the Company announced that the first patient had been dosed in Part 2a of the Phase 2 DENALI clinical trial ( NCT05128825) of azenosertib in patients with Cyclin E1+ platinum-resistant ...

InnoCare gets China NMPA approval for Minjuvi in combo with lenalidomide to treat relapsed or refractory diffuse large B-cell lymphoma: Beijing, China Friday, May 23, 2025, 13:00 ...

-Under the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to ...

We lifted the UEFA Women’s Champions League once more, this time in front of our supporters outside Emirates Stadium ...

Tadaaki Taniguchi, M.D., Ph.D., Chief Research & Development Officer, Astellas | Astellas’ Chief R&D Officer, Tadaaki ...